Claims
- 1. A compound of the Formula
- 2. The compound of claim 1, wherein L1 is a bond and wherein X is substituted or unsubstituted dihydroquinoline, tetrahydroquinoline, pyranopyridine, dihydropyranopyridine, thiapyranopyridine, dihydrothiapyranopyridine, dihydronaphthyridine, or tetrahydronaphthyridine.
- 3. The compound of claim 1, wherein L1 is alkylene as defined in claim 1, CO or SO2 and X is a monocyclic (5-6 membered) or fused bicyclic (9-12 membered) unsubstituted or substituted ring system containing at least one heteroatom selected from N, O and S.
- 4. The compound of claim 3, wherein X is an optionally substituted imidazole, oxazole, thiazole, benzimidazole, benzothiazole, or benzoxazole.
- 5. The compound of claim 1, wherein Z is hydrogen.
- 6. The compound of claim 1, wherein Y is an optionally substituted imidazole, benzimidazole, pyridine, pyridine, pyrimidine, or phenyl, wherein the ring nitrogen may optionally be oxidized.
- 7. The compound of claim 6, wherein said optional substituents are selected from the group consisting of halogen, nitrile, alkyl, —OR, —SR, —NR2, —NRCOR, —OOCR, —COR, —CONR2, —COOR, —NO2, —NOH, —CF3, where R is H or alkyl (1-6C).
- 8. The compound of claim 1 which is of the formula
- 9. The compound of claim 8 wherein all of Z1, Z2 and Z3 are CH or CR′.
- 10. The compound of claim 8 wherein Z3 is N and L3 is CO.
- 11. The compound of claim 9 or 10 wherein one of L2 and L3 is SO2 and the other is a bond or CH2.
- 12. The compound of claim 9 or 10 wherein one of L2 and L3 is CO and the other is a bond or CH2.
- 13. The compound of claim 1 wherein L1 is alkylene (2-5C) wherein one C may optionally be replaced by N and which may optionally be substituted by a bridging alkylene (3-4C).
- 14. The compound of claim 13 which is of the formula
- 15. The compound of claim 14 wherein all of Z1, Z2 and Z3 are CH or CR′.
- 16. The compound of claim 14 wherein Z3 is N and L3 is CO.
- 17. The compound of claim 15 or 16 wherein one of L2 and L3 is SO2 and the other is a bond or CH2.
- 18. The compound of claim 15 or 16 wherein one of L2 and L3 is CO and the other is a bond or CH2.
- 19. A pharmaceutical composition for treatment of conditions which are modulated by the chemokine receptor CXCR4 or CCR5 which comprises an effective amount of at least one compound of claims 1-18.
- 20. The use of a compound of any of claims 1-18 for the manufacture of a medicament for treating conditions modulated by the chemokine receptor CXC4 or CCR5.
- 21. The use of a compound of any of claims 1-18 in the manufacture of a medicament for the treatment of HIV or FIV infected patients.
- 22. The use of a compound of any of claims 1-18 for the manufacture of a medicament for treating conditions modulated by a chemokine receptor in a mammalian subject.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C.§ 119(e) to provisional application Ser. No. 60/233,087 filed Sep. 15, 2000 and to U.S. Ser. No. 60/234,816 filed Sep. 22, 2000. The contents of these applications are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60234816 |
Sep 2000 |
US |
|
60233087 |
Sep 2000 |
US |